H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock

The setup is less about the near-term read-through from one trial update and more about whether ORIC can convert a clean safety narrative into a durable valuation rerating before the market re-prices the program as another me-too epigenetic asset. The key second-order effect is on probability-weighted partnering: if rinzometostat keeps avoiding the malignancy baggage that has handicapped this class, ORIC’s bargaining power improves materially, because larger oncology partners will pay up for de-risked biology with cleaner regulator optics.

FULC is the clearest loser, but the bigger implication is for the PRC2 bucket as a whole. Negative spillovers from one failed program often compress multiples across adjacent early-stage epigenetic names for weeks, even when the underlying mechanism is different; that creates a window for relative-value trades rather than outright directional shorts. PFE matters mainly as a comparator: if Pfizer’s competing asset continues to look merely adequate, ORIC can still win on differentiation even without blowout efficacy, because safety plus tolerability can dominate in combination regimens where chronic dosing matters.

The main contrarian risk is that the market may be over-anchoring on a clean toxicology package and underweighting the far more important issue: eventual efficacy durability and whether the PSA signal translates into OS or rPFS in a crowded prostate landscape. If subsequent data show plateauing responses or more dose pressure, today’s safety premium will fade quickly over the next 1-2 quarters. Conversely, a positive partnership or expansion update within 3-6 months could force a sharp re-rating because current pricing implies limited confidence in a path to commercial relevance.

For now, the move looks under-owned rather than over-extended, but the trade is likely to be choppy: ORIC can rerate on headlines while FULC remains a slow-burn loser from class contamination. The best risk/reward is to express the view as a relative trade with defined downside, not as a naked long biotech beta bet.